Given the high prevalence of PIK3CA mutations in human carcinomas, and considering the emerging role of PIK3CA mutation status in the treatment selection process, these findings may have a significant impact on the design of future trials evaluating the potential of combining metformin with targeted therapy. This evidence concerns the gene PIK3CA and carcinoma.